Migraines

• Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? (PubMed)
• Effects of anandamide in migraine: data from an animal model (PubMed)
• Cannabinoids and hallucinogens for headache (PubMed)
• The endocannabinoid system and migraine (PubMed)
• Variations in the cannabinoid receptor 1 gene predispose to migraine (PubMed)
• Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model (The Journal of Headache and Pain)
• Clinical Endocannabinoid Deficiency (CECD): Can this Concept Explain Therapeutic Benefits of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome and other Treatment-Resistant Conditions? (Neuroendocrinology Letters)
• Clinical endocannabinoid deficiency (CECD) revisited (Neuroendocrinology Letters)
• Endocannabinoids in the Brainstem Modulate Dural Trigeminovascular Nociceptive Traffic via CB1 and “Triptan” Receptors: Implications in Migraine (The Journal of Neuroscience)
• The endocannabinoid system and migraine (ScienceDirect)